Abstract
Phenyl-N-tert-butylnitrone (PBN) protects rat retinas against light damage. Because the degenerative process involved in light damage and inherited retinal degeneration both lead to a common final cell death, apoptosis, we used transgenic rats with a P23H or S334ter rhodopsin mutation to test the effects of PBN on retinal degeneration and light damage and the susceptibility of the transgenic rats to light damage. In the first study, 3-week-old mutant and wild-type rats were given no drug, 0.25% PBN in drinking water, or 0.25% PBN in drinking water plus three daily intraperitoneal injections of PBN (100 mg/kg, i.p., every 8 hr). Electroretinograms were recorded at postnatal day 49, after which the rats were killed for morphometric analysis. There was no photoreceptor rescue by PBN in P23H or S334ter rats, as evidenced by equivalent loss of function and photoreceptor cells in the three treatment groups. In the second study, P23H, S334ter, and wild-type rats were exposed for 24 hr to 2700 lux light. The rats were untreated or treated with PBN (50 mg/kg per injection, every 6 hr, starting before exposure). ERGs were recorded before and 1 d after exposure. Animals were killed 6 d later for morphometric analysis. PBN protected wild-type and P23H but not S334ter retinas from light damage. S334ter retinas were relatively less susceptible to light damage than P23H and wild-type rats. The results suggest that the initiating event(s) that causes photoreceptor cell death in the mutated rats is different from that which occurs in light damage, although both ultimately undergo an apoptotic cell death.
- neuroprotection
- inherited retinal degeneration
- free radical
- phenyl-N-tert-butylnitrone
- electroretinography
- light damage
Introduction
Retinitis pigmentosa (RP) is a genetically and clinically heterogeneous group of retinal degenerative diseases, affecting ∼1 in 3500 people (Pagon, 1988). Symptoms include night blindness, progressive loss of peripheral visual field, and eventual loss of central vision caused by degeneration of photoreceptor cells. A number of genes responsible for RP have now been identified (Dryja and Li, 1995; Sullivan and Daiger, 1996), most of which are expressed specifically in photoreceptor cells, and the degeneration primarily affects photoreceptor cells. There are now >100 different mutations in the rod photoreceptor visual pigment rhodopsin that are associated with RP (RetNet; http://sph.uth.tmc.edu/Ret-Net/). The rhodopsin molecule has distinct regions that are specialized for light capture, initiation of the phototransduction cascade, and rapid deactivation after light absorption. Other regions ensure its proper folding and sorting within the photoreceptor membranes. Therefore, it is not surprising that the phenotype depends on the location of the mutation and may be expressed as either dominant or recessive RP. Transgenic rat lines have been developed that express one of two mutated rhodopsin genes, as well as the wild-type gene (Steinberg et al., 1996). In S334ter rats, the opsin transgene contains a termination codon at residue 334, resulting in the expression of a rhodopsin protein lacking the 15 C-terminal amino acids. In P23H rats, the opsin transgene contains a histidine substitution at the proline 23 position. The P23H transgenic rats have a slow rod degeneration with normal cone function initially, consistent with the clinical findings of P23H patients (Machida et al., 2000).
Although transgenic rats and other animal models have been developed to study the cellular etiologies of inherited retinal degenerations and to test potential therapies, there is still little known about the molecular mechanisms leading to photoreceptor cell death, and there are no adequate therapies for RP at present. Because mutations in integral, peripheral, and soluble proteins can all lead eventually to cell death, there must be a number of initiating events. However, most studies to date have found that the photoreceptor cells undergo apoptosis as the final common death pathway converging the primary defects (Remé et al., 1998). Light-induced damage represents a suitable model system to study retinal degeneration, because apoptotic cell death underlies both light-induced damage (Li et al., 1995; Organisciak et al., 1995) and inherited retinal degeneration (Chang et al., 1993; Lolley et al., 1994; Portera-Caillau et al., 1994; Tso et al., 1994) in various animal models. This suggested that strategies used in light-damage studies could be applied to animals with inherited retinal degenerations. Using this approach, LaVail and coworkers showed that the intravitreal administration of basic FGF (bFGF) (Faktorovich et al., 1992) and other neurotrophic factors (LaVail et al., 1992) rescued photoreceptors of albino rats from light damage. bFGF also prevented inherited retinal degeneration in the Royal College of Surgeons (RCS) rat (Faktorovich et al., 1990). Other classes of survival factors that protect photoreceptors from light damage or mutations have also been discovered, including α-2-adrenergic agonists (Wen et al., 1996), a melatonin receptor antagonist (Sugawara et al., 1998), a caspase-3 inhibitor (Liu et al., 1999), pigment epithelium-derived factor (Cayouette et al., 1999; Cao et al., 2001), lens epithelium-derived growth factor (Machida et al., 2001), heat shock protein (Yu et al., 2001), and additional neurotrophic factors such as glial cell line-derived neurotrophic factor (Frasson et al., 1999) and ciliary neurotrophic factor (LaVail et al., 1998). The antioxidants vitamin C (Organisciak et al., 1991) and dimethylthiourea (Organisciak et al., 1992) have been shown to protect against light-induced damage. Recently, Organisciak et al. (2002) found that dimethylthiourea protected P23H and S334ter transgenic rats from light damage; its effect on the inherited retinal degeneration was not studied.
Phenyl-N-tert-butylnitrone (PBN) is a free radical scavenger that is frequently used as a spin trap agent in free radical research. PBN given intravenously to gerbils was found to be neuroprotective in an ischemia–reperfusion experimental paradigm (Novelli et al., 1986a). More recently, PBN has been shown to have a variety of pharmacological effects, including reduction in the mortality associated with endotoxin shock (McKechnie et al., 1986; Novelli et al., 1986b; Hamburger and McCay, 1989; Miyajima and Kotake, 1995), neuroprotection in ischemia-reperfusion and aging models (Phillis and Clough-Helfman, 1990; Carney et al., 1991), amelioration of the CNS damage associated with the human immunodeficiency virus envelope protein glycoprotein 120 (Tabatabaie et al., 1996), and prevention of streptozotocin-induced diabetes in mice (Tabatabaie et al., 1997). Other reports have indicated that the action of PBN is related to the expression of various cytokine genes and to the activation of the transcription factor nuclear factor κB (Kotake et al., 1998) and activator protein-1 (AP-1) (Sang et al., 1999).
We have shown that PBN protects the retina against light-induced apoptosis (Ranchon et al., 2001, 2002). Because of the common apoptotic degenerative pathway in both inherited and light-induced retinal degenerations, and because some of the agents described above were neuroprotective in both types of degeneration, we tested the effect of chronic administration of PBN on the degeneration induced by the S334ter and P23H transgenes in the rat retina. In addition, because P23H rats (Nir et al., 2001; Organisciak et al., 2002) and mice (Naash et al., 1996a,b; Wang et al., 1997) are more susceptible to light damage than wild-type animals, and the onset of degeneration in P23H-3 and S334ter-4 rats occurs between postnatal day 10 (P10) and P15, approximately coinciding with eye opening (P12), we considered that light might be a contributing factor in the degenerative mechanism. Therefore, we tested the effect of PBN on light-induced damage in P23H and S334ter rat retinas.
Materials and Methods
Materials. PBN was synthesized by Dr. Yashige Kotake (Oklahoma Medical Research Foundation, Oklahoma City, OK). All other chemicals were reagent grade and purchased from Sigma (St. Louis, MO), except as indicated.
Animals. Wild-type control rats used in this study were Sprague Dawley rats (Harlan, Indianapolis, IN). Heterozygous P23H-3 and S334ter-4 rats were generated by mating homozygous P23H (line 3) or S334ter (line 4) rats with wild-type Sprague Dawley rats. (The transgenic line designations are omitted hereafter for brevity.) All animals were born and kept in dim cyclic light (12 hr light/dark cycle; 5–10 lux) and had ad libitum access to lab chow and water. These two particular lines were chosen because they show a significant degree of retinal degeneration by 7 weeks of age, which would allow the determination of any rescue by the various experimental treatments. The animal care strictly conformed to the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Vision and Ophthalmic Research and the University of Oklahoma Health Sciences Center Guidelines for Animals in Research. All protocols were reviewed and approved by the Institutional Animal Care and Use Committees of the University of Oklahoma Health Sciences Center and Dean A. McGee Eye Institute.
Electroretinography. Rats were dark-adapted overnight and prepared under dim red light for the ERG study. They were anesthetized with intramuscular injections of ketamine (120 mg/kg body weight) and xylazine (6 mg/kg body weight). One drop of 1% tropicamide was applied to the cornea to dilate the pupil. The white light stimulus used to evoke ERGs was delivered in 10 msec pulses by an integrating sphere (Lab-sphere, North Sutton, NH) at an interval between flashes of 60 sec. ERGs were recorded with gold electrodes at six intensities presented in ascending order, starting below threshold, to obtain the b-wave sensitivity curves. The software program Origin 6.0 (Microcal Software, Northampton, MA) was used to fit the data of each rat, giving the saturated a-wave (Amax) and b-wave (Bmax) amplitudes.
Histology. Rats were killed by carbon dioxide asphyxiation for light microscopic evaluation of retinal structure. Immediately after death, eyes were excised, placed in fixative (4% paraformaldehyde, 2% trichloroacetic acid, 20% isopropyl alcohol, 2% zinc chloride, and 72% distilled water), and embedded in paraffin. Sections of 5 μm were cut along the vertical meridian through the optic nerve. Illustrations of photoreceptor degeneration in the P23H line 3 and S334ter line 4 mutant rhodopsin transgenic rats (Lewin et al., 1998; Liu et al., 1999; Machida el al., 2000; Green et al., 2001; Nir et al., 2001; Organisciak et al., 2002) and the protection from light damage by PBN (Ranchon et al., 2001, 2002) have been presented previously and will not be repeated here. Instead, a quantitative, morphometric assessment of photoreceptor cell loss was performed. The thickness of the outer nuclear layer (ONL) was measured at 0.5 mm distances from the optic nerve to the inferior and superior ora serrata and plotted as shown in Figure 2. The area under the curves was integrated using the Origin 6.0 program (Microcal Software), and the results were used for quantitative comparisons. The ONL area is proportional to ONL thickness and is a measure of the number of viable photoreceptor cells (Williams and Howell, 1983; Michon et al., 1991).
Rhodopsin measurement. Thirty-day-old rats were dark-adapted overnight, killed the next morning, and their retinas removed under dim red light. Two retinas from the same rat (n = 6) were homogenized in 500 μl of 67 mm phosphate buffer containing 2% N-octyl-β-d-glucopyranoside (Calbiochem, La Jolla, CA) and shaken at 4°C for 1 hr. Hydroxylamine (25 μl, 1 m) was added, and the samples were centrifuged at 4°C for 30 min at 27,000 × g. The clear supernatant was scanned from 400 to 800 nm (Ultrospec 3000; Amersham Biosciences, Cambridge, UK), after which the samples were bleached by exposure to the room light for at least 15 min and scanned again. The difference in absorption at 500 nm was used to determine the concentration of rhodopsin using a molar extinction coefficient of 42,000 (Shichi et al., 1969).
Effect of PBN on inherited retinal degeneration. In each strain (wild-type, P23H, and S334ter), rats were divided into three groups of 10 rats each (90 rats total). The first group was given 0.25% PBN in drinking water, the second group was given 0.25% PBN in drinking water plus three intraperitoneal injections (800, 1400, and 2000) of PBN (100 mg/kg body weight, in an aqueous solution of 25 mg/ml PBN), and the third group was given only drinking water. The treatments were begun at P21 and continued until P49. ERGs were recorded at P49, after which the animals were killed and retinas taken for morphologic examination.
Light damage paradigm. Control ERGs were recorded on 8 wild-type, 20 S334ter, and 20 P23H rats (P38–P41). At P45–P52, rats from each strain were divided into two subgroups that were dark-adapted overnight before being exposed for 24 hr to constant illumination of 2700 lux intensity. One subgroup was treated with PBN (aqueous solution, 50 mg/kg, i.p.) every 6 hr over the 24 hr of light exposure, the first treatment starting 0.5 hr before exposure (Ranchon et al., 2001). The other subgroup was not treated. No sham injections were done, because they have been shown to have no effect (Ranchon et al., 1999, 2001). After light exposure, the animals were placed in the dark for 24 hr and ERGs were recorded the next day (day 1). Thereafter, the animals returned to dim cyclic light until they were killed 5 d later for morphometric analysis.
Statistical analysis. ANOVA was performed on the derived parameters and ONL areas to determine the effects of treatments and/or light exposure on the ERG values and the ONL areas. A significance level of p = 0.05 was set. If ANOVA was significant, multiple comparisons were performed to decide which pairs of mean values were different. Significant differences across groups were assessed using the post hoc Scheffé test with the significance level set at p = 0.05 (Scheffé, 1959)
Results
Effect of PBN on inherited retinal degeneration
Animals were untreated or treated with 0.25% PBN in drinking water with or without PBN injections from P21 to P49, at which time retinal structure and function were evaluated. In the untreated groups, retinal function was reduced in the P23H and S334ter rats compared with that of wild-type rats (Fig. 1A). The maximal b-wave amplitude (Bmax) was reduced significantly to 54% in P23H animals and 51% in S334ter animals (p < 0.0001), with no significant difference found between the two transgenic lines. PBN treatment did not alter the b-wave amplitudes in wild-type rats (Fig. 1B). PBN treatment also had no significant protective effect on retinal function in the mutant rhodopsin transgenic rats (Fig. 1C,D), indicating that the drug did not protect their retinal photoreceptors from degeneration.
Measurement of ONL areas in untreated wild-type, P23H, and S334ter rat retinas showed a significant reduction in P23H (16%) and S334ter (31%) compared with wild type (p < 0.008 and p < 0.00001, respectively), with photoreceptor loss in both superior and inferior hemispheres (Fig. 2A). There was no significant effect of PBN treatment on ONL area in any of the test groups (Fig. 2B–D).
Light damage susceptibility
Because PBN had no protective effect on the photoreceptor degeneration because of the genetic mutations, we tested whether it could provide protection against light damage in the mutant animals. Wild-type, P23H, and S334ter rats were divided into two subgroups: one group was not treated, and the other was given five intraperitoneal injections of aqueous PBN (50 mg/kg per injection, the first given 0.5 hr before light exposure) (Ranchon et al., 2001). Both subgroups were exposed to continuous illumination (2700 lux) for 24 hr. Retinal function was determined by ERG analysis before and 1 d after light treatment. In wild-type (Fig. 3A,B) and P23H (Fig. 3C,D) untreated rats, 24 hr of light exposure resulted in complete loss of the a-wave and b-wave responses of the ERG. However, in the untreated S334ter animals (Fig. 3E,F), retinal function was only partially reduced by the same light treatment [Amax was 20 ± 14% (p < 0.0001) and Bmax was 40 ± 14% (p < 0.0001) compared with their respective values before exposure to the damaging light]. Treatment with PBN had a significant effect on the preservation of function in the wild-type and P23H rats. Amax and Bmax values were preserved (p < 0.00001) to some extent in wild-type (42 ± 9 and 62 ± 16%, respectively) and P23H (16 ± 9 and 49 ± 19%, respectively) animals. However, PBN treatment was without effect in the S334ter rats; Amax and Bmax values were 29 ± 15 and 55 ± 16%, respectively, which although slightly higher than the values for untreated animals, were not significantly different.
Exposure of untreated rats to 2700 lux of continuous illumination caused loss of photoreceptor cells in all three groups, with wild-type (Fig. 4A) and P23H (Fig. 4B) animals being more affected than S334ter animals (Fig. 4C). Values for the 7-week-old control animals used in the first study (Fig. 2) are presented here for comparison. In wild-type rats, light stress induced a significant reduction of the ONL area to 3.6% of unexposed wild-type retinas in the superior hemispheres and to 14% of unexposed wild-type retinas in the inferior hemispheres (Fig. 4A). In P23H and S334ter animals, the ONL thickness was affected to the same extent in superior and inferior hemispheres of the retina, and the integrated area was reduced to 10% of unexposed wild-type in P23H rats (Fig. 3B) and to 40% of unexposed wild-type in S334ter rats (Fig. 3C).
In PBN-treated groups, the ONL area of wild-type (Fig. 4A) and P23H (Fig. 4B) rat retinas was significantly preserved to 54% (wild type) (p < 0.00001) and 50% (P23H) (p < 0.00001), respectively, in the superior retina and to 92% (wild type) (p < 0.03) and 72% (P23H) (p < 0.004), respectively, in the inferior retina of comparable hemispheres in unexposed rats. In the S334ter rats, the ONL area (Fig. 4C) was significantly preserved to 74% (p < 0.005) in the inferior retina by PBN treatment, but not in the superior hemisphere.
Comparison of rhodopsin content and ONL area in wild-type, P23H, and S334ter rats
Before exposure to the damaging light, the status of the retinas in each strain was determined in P30 animals. The ONL area was significantly reduced to 85% of wild-type controls in P23H (p < 0.014) and to 70% of wild-type in S334ter (p < 0.0001) retinas (Table 1), and there was a significant difference (p < 0.01) between P23H and S334ter retinas. The rhodopsin content was reduced to 61% in P23H (p < 0.0001) and 36% in S334ter (p < 0.00001) retinas (Table 1). Retinal function was reduced in the two transgenic strains; Amax was 55 ± 11% in the P23H (p < 0.002) and 36 ± 5% in the S334ter (p < 0.0001) rats, compared with that in wild-type rats. Amax was also significantly different between P23H and S334ter rats (p < 0.005). Bmax was significantly (p < 0.0001) reduced to 55 ± 4% in P23H rats and to 54 ± 5% in S334ter rats compared with the wild-type (1620 ± 155 μV) rats (Table 1). Bmax was not significantly different between S334ter and P23H rats.
Discussion
Light damage to photoreceptors is triggered by the excessive absorption of photons by the visual pigment rhodopsin (Grimm et al., 2000), and the vulnerability of these cells is positively correlated to the rhodopsin content (Noell et al., 1966; Noell and Albrecht, 1971; Remé et al., 1998). In this study, we found that the critical determinant for light-damage sensitivity is not solely the rhodopsin content, because P23H rats had a lower retinal rhodopsin content than the wild-type rats, yet they were as susceptible to light damage as the wild types. This is consistent with the finding by Wenzel et al. (2001a) that dark-adapted rhodopsin level does not necessarily correlate with photons caught in the light, and that the steady-state bleach level and the regeneration rate are also important determinants.
The S334ter rats were relatively more resistant to light damage than the P23H rats. The resistance to light damage may be attributable in part to the significantly lower levels of rhodopsin compared with the levels seen in P23H rats, but other factors may be involved. For example, at least some of the rhodopsin is mis-sorted in S334ter photoreceptors (Green et al., 2000). At present, however, we do not know whether other factors in photon capture or rhodopsin regeneration (Wenzel et al., 2001a) or other genetic factors (Danciger et al., 2000; Hao et al., 2002) that influence the susceptibility to light damage are different in the two mutant lines. Thus, the exact cause of the reduced susceptibility of S334ter rats to light damage remains to be determined.
In this study, we found that acute administration of PBN protects wild-type and P23H but not S334ter rat retinas from the damaging effect of light. This suggests that the protection by PBN is dependent on the normal activation–deactivation of the rhodopsin molecule. In wild-type and P23H rats, PBN protection might involve mechanisms other than free radical scavenging, such as a downregulation of the rhodopsin regeneration rate or effects on cellular metabolism. PBN has also been shown to reduce basal protein phosphorylation in primary rat glia (Robinson et al., 1999), and phosphorylation is a major step in rhodopsin regeneration (Bennett and Sitaramayya, 1988; McDowell et al., 2001). This may explain why PBN was less effective in the S334ter rats, because S334ter-rhodopsin is missing the phosphorylation sites required for the inactivation process.
Because PBN protected wild-type and P23H rat retinas from light damage but did not protect P23H (or S334ter) from inherited degeneration, the underlying mechanisms that cause these two types of degeneration and the action of PBN on them must be different. Although relatively little is known about the molecular and cellular mechanisms of the inherited retinal degenerations compared with those of light damage, a few points can be suggested from the present findings. First, apoptosis is known to be the “final cell death pathway” in both light-induced and hereditary retinal degenerations. The fact that PBN protects against light-induced but not against P23H-induced or S334ter-induced degeneration suggests that PBN does not interact directly with the apoptotic pathway or that the apoptotic pathway in the mutation-induced and light-induced degeneration are different. This latter possibility must be considered until shown otherwise in view of the recent demonstration of two apoptotic pathways in light-induced retinal degeneration (Hao et al., 2002).
The second point that can be made from the present data on differential effects of PBN on inherited and light-induced degenerations concerns the role of free radicals in the degenerative process. Chronic administration of PBN for 4 weeks did not protect against inherited retinal degeneration induced by the expression of the P23H or S334ter mutant rhodopsin transgenes. Because PBN was injected at ∼60 mg/day per rat and/or 0.25% PBN was present in the drinking water, the lack of protection cannot be attributed to a too small amount of the drug, but rather suggests that: (1) free radicals do not play an early role in the hereditary degenerative process, (2) radicals are involved too far down in the cascade of degenerative events for the cells to be rescued, or (3) other cellular pathways affected by PBN are not involved in inherited retinal degenerations.
The fact that S334ter rats are less susceptible to light damage than P23H rats and are the least rescued by PBN and the fact that P23H rats are not rescued to the same extent as wild type are consistent with PBN as a protective agent against the primary events in light-induced cell death but not on the mutation-induced pathways. PBN may act as an antioxidant/free radical scavenger in the early stages of light damage. There is probably a complex interaction between the secondary processes of light damage and inherited degeneration. The effects of light on cells already stressed by photoreceptor mutations probably differ according to the interactions of light damage with the pathways of degeneration in each type of mutation. Although these suggestions would explain our current findings, they remain to be shown experimentally.
Recent studies provide some insight into the differences in the mechanisms of cell death in light damage and inherited degenerations with molecules other than PBN. Mice lacking the protooncogene c-fos were protected from light damage (Hafezi et al., 1997), whereas the transcription factor AP-1 was increased during bright-light stress (Hafezi et al., 1999). Suppression of AP-1 expression with steroids protected retinas from light damage (Wenzel et al., 2001b). In retinal degeneration mutants, however, the absence of c-fos resulted in no protective effect in rd/rd (Hafezi et al., 1998) and rhodopsin knock-out mice (Hobson et al., 2000). Similarly, overexpression of the survival-promoting growth factor FGF-2 reduces hyperoxia-induced photoreceptor cell death in mice but does not reduce cell death in rd/rd or Q344ter mutant rhodopsin transgenic mice (Yamada et al., 2001). These studies, along with our present findings, provide substantial evidence that the mechanisms of cell death initiation in the mutant mice are different from those in light damage, although apoptosis is the ultimate cause of cell demise in each case.
Substantial effort in retinal degeneration research has focused on a protective strategy to slow the rate of retinal degeneration. There exists a significant genetic heterogeneity in RP phenotypes, even in patients with the same gene mutation, and a large number of mutations exist in multiple retinal genes leading to the common pathway of photoreceptor cell death. Specific gene therapies, such as antisense or ribozymes (Lewin et al., 1998), may not readily treat a significant fraction of patients. As a result, it is important to develop a generalized survival factor therapy that does not target the mutant gene product, but rather alters the photoreceptor or its environment in a manner that promotes cell survival. The use of light damage and S334ter and P23H rats in combination allows the design of therapies for animal models that mimic human disorders, yet provides different degeneration and gene defects with which to test such generalized therapies.
Footnotes
This work was supported by grants from the National Institutes of Health (EY00871, EY01919, EY02162, EY06842, EY04149, EY12190, and RR17703), Research to Prevent Blindness (RPB), The Foundation Fighting Blindness, Oklahoma Center for the Advancement of Science and Technology–Oklahoma Applied Research Support, Samuel Roberts Nobel Foundation, The IPSEN Foundation, and Presbyterian Health Foundation. M.M.L. is an RPB senior scientist investigator. We gratefully acknowledge the assistance of Mark Dittmar in the breeding and husbandry of the animals and in the ERG measurements.
Correspondence should be addressed to Dr. Isabelle Ranchon, Laboratoire de Biophysiques Sensorielles, Facultés de Médecine et de Pharmacie, 28 Place Henri Dunant, 63000 Clermont-Ferrand, France. E-mail: isabelle.ranchon{at}uclermont1.fr.
Copyright © 2003 Society for Neuroscience 0270-6474/03/236050-08$15.00/0